Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.

Area of Science:

• Genetics
• Oncology
• Medical Guidelines

Background:

• Pathogenic variants in BRCA1 and BRCA2 genes are primary drivers of hereditary breast cancer.
• BRCA gene testing is increasingly vital for determining eligibility for PARP inhibitor (PARPi) therapies.
• Current clinical practice necessitates updated guidelines for BRCA testing due to its role in both prevention and treatment.

Purpose of the Study:

• To provide integrated recommendations for BRCA testing.
• To identify individuals who could benefit from genetic counseling and risk-reducing strategies.
• To update germline and tumor testing indications for PARPi therapies and personalized breast cancer management.

Main Methods:

• An international expert group, commissioned by the SFMPP, developed the guidelines.
• Methodology included a systematic literature review, risk assessment models, and expert consensus.
• Evaluation focused on the likelihood of BRCA mutations (BRCAm) and the therapeutic value of BRCAm status for PARPi therapy and breast cancer management.

Main Results:

• The guidelines address testing for hereditary breast cancer, PARPi therapy eligibility, and personalized management of early and metastatic breast cancer.
• Recommendations cover both germline and tumor testing, including considerations for rapid processing and analysis.
• The integrative approach aims to standardize BRCA testing practices globally.

Conclusions:

• These international guidelines offer a comprehensive framework for updating and standardizing BRCA testing.
• Clinicians can utilize these recommendations to improve the identification and management of patients with BRCA-related cancers.
• The guidelines facilitate informed decision-making for genetic counseling, risk reduction, and targeted therapies.